MARKET

IMDX

IMDX

Insight Molecular Diagnostics Inc.
NASDAQ
5.24
-0.34
-6.09%
After Hours: 5.11 -0.13 -2.48% 17:06 12/05 EST
OPEN
5.58
PREV CLOSE
5.58
HIGH
5.63
LOW
5.21
VOLUME
27.01K
TURNOVER
--
52 WEEK HIGH
8.51
52 WEEK LOW
1.922
MARKET CAP
150.20M
P/E (TTM)
-1.8534
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMDX last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at IMDX last week (1117-1121)?
Weekly Report · 11/24 10:42
Weekly Report: what happened at IMDX last week (1110-1114)?
Weekly Report · 11/17 10:43
Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating
Seeking Alpha · 11/14 19:59
Fourteen new option listings on November 12th
TipRanks · 11/12 13:30
This Biotech Stock Is Up 158% in a Year. What’s Driving It Higher?
Barchart · 11/12 10:15
OncoCyte Corp’s Earnings Call: Progress Amid Challenges
TipRanks · 11/12 00:21
Insight Molecular Diagnostics Reaffirms Mid-2026 Launch Plans
Reuters · 11/11 18:10
More
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Webull offers Insight Molecular Diagnostics Inc stock information, including NASDAQ: IMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMDX stock methods without spending real money on the virtual paper trading platform.